Literature DB >> 4011338

Effect of taurine supplements on fat absorption in cystic fibrosis.

P B Darling, G Lepage, C Leroy, P Masson, C C Roy.   

Abstract

Patients with cystic fibrosis have an increased proportion of glycine conjugated bile acids with diminished tauroconjugates which could contribute to fat malabsorption. Twenty-two CF children with documented steatorrhea were supplemented with taurine capsules (30 mg/kg/day) and placebo during separate 6-month treatment periods. Alteration of the glycine/taurine conjugation pattern was verified in two patients who showed a predominance of tauroconjugates as a result of taurine supplementation. On taurine, steatorrhea was reduced (p less than 0.05) by 17.6 +/- 9.7% in 19 patients who completed the study as was the excretion of long-chain saturated fatty acids. There was no change in linoleic acid (C 18:2) excretion. In the 10 patients with a more severe degree of steatorrhea the decrease in fat loss approached 20% and a close relationship was found (r = 0.84, p less than 0.01) between the extent of the fatty acid loss on placebo and the decrease of this loss on taurine. A linear relationship was found between the percentage decrease of individual fatty acids and their log solubility in water. No change was found in the daily excretion of bile acids, neutral sterols, and nitrogen. Fasting plasma fatty acids, cholesterol, and triglycerides were also unchanged. Monitoring of growth over the two 6-month periods revealed a marginal (p less than 0.1) increase of weight velocity expressed as a percentage expected for age (83.4 +/- 11.3----117.1 +/- 16.5). The increase in height velocity in response to taurine showed a more modest trend (95.3 +/- 7.8----110.7 +/- 10.6).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4011338     DOI: 10.1203/00006450-198506000-00015

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  16 in total

Review 1.  Rationale of modern dietary recommendations in cystic fibrosis.

Authors:  J M Littlewood; A MacDonald
Journal:  J R Soc Med       Date:  1987       Impact factor: 5.344

2.  Effect of dietary fat and residues on fecal loss of sterols and on their microbial degradation in cystic fibrosis.

Authors:  C Leroy; G Lepage; C L Morin; J M Bertrand; O Dufour-Larue; C C Roy
Journal:  Dig Dis Sci       Date:  1986-09       Impact factor: 3.199

Review 3.  Gastrointestinal tract and nutrition in cystic fibrosis: pathophysiology.

Authors:  J A Dodge
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

4.  Failure of taurine to improve fat absorption in cystic fibrosis.

Authors:  G N Thompson
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 5.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

Review 6.  Oral bile acids in cystic fibrosis-associated liver disease.

Authors:  C Colombo; A Crosignani; M G Apostolo; M T Marzano; N Bettinardi; A Giunta
Journal:  J R Soc Med       Date:  1994       Impact factor: 5.344

Review 7.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

8.  Relationships between essential fatty acid levels, pulmonary function and fat absorption in pre-adolescent cystic fibrosis children with good clinical scores.

Authors:  G N Thompson
Journal:  Eur J Pediatr       Date:  1989-01       Impact factor: 3.183

Review 9.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Soe Moe; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

10.  Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations.

Authors:  K H Hsieh; M F Shaio; T N Liao
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.